---
title: "Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305535476.md"
datetime: "2026-11-14T06:32:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305535476.md)
  - [en](https://longbridge.com/en/news/305535476.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305535476.md)
generator: "portal-rs"
---

# Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes

(Recasts; adds details, context throughout)

SHANGHAI/BEIJING, Nov 14 (Reuters) - GLP-1 drugs from Pfizer (PFE.N) and Innovent Biologics (1801.HK) will be added to China’s state-run health insurance scheme from January 1 for patients with type 2 diabetes, the National Healthcare Security Administration said on Saturday, in a fresh challenge to Danish rival Novo Nordisk (NOVOb.CO) .

China has the highest number of adults with diabetes in the world, ​according to an estimate by the International Diabetes Federation. Pfizer’s ecnoglutide and Innovent’s mazdutide belong to the class of GLP-1 ​receptor agonist drugs already included in China’s state insurance list from firms such ​as Novo, Eli Lilly (LLY.N) and Guangzhou Innogen Pharmaceutical (2591.HK) .

Novo’s Ozempic joined China’s reimbursement list in ​2022, followed by Lilly’s Mounjaro and Innogen’s efsubaglutide alfa from this year for patients with ​type 2 diabetes. Inclusion in the national reimbursement list makes drugs more widely available ‌in ⁠the country of 1.4 billion people, though an increase in sales volume often comes with lower prices.

The GLP-1 class of weight drugs mimics a gut ⁠hormone to curb appetite and regulate blood sugar in patients with diabetes.

Sales of Ozempic injector pens in the greater China region of mainland China, Taiwan and Hong Kong — Novo’s largest market after the US — slipped 7% to about 5.4 billion Danish crowns ($850 ​million) in 2025.

Other treatments to be added to the list include two Eli Lilly drugs for ulcerative colitis and Crohn’s disease, as well as a CAR-T therapy from JW Therapeutics (2126.HK) , according to company statements.

The CAR-T therapy, which engineers patients’ immune cells to recognise and kill cancer cells, was the first to be included in the reimbursement list.

### Related Stocks

- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [02126.HK](https://longbridge.com/en/quote/02126.HK.md)
- [02591.HK](https://longbridge.com/en/quote/02591.HK.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md)
- [Pfizer Signs Licensing Deal With Starna Therapeutics for Autoimmune Disease Treatments](https://longbridge.com/en/news/305966590.md)
- [Datapharm expands SRD Search into France](https://longbridge.com/en/news/305684420.md)
- [Innovent adds seven products to China’s 2026 NRDL](https://longbridge.com/en/news/305580225.md)
- [UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO  Ophthalmology R&D](https://longbridge.com/en/news/305767362.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**